CRClaude Jeffrey Renaud

Claude Jeffrey Renaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claude Jeffrey Renaud has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mapping AI Ethics Integration in Postgraduate Health Professions Education: A Scoping Review Through the Lenses of Principlism and Transformative Learning

    by Tricia Mae Wong, Ang Yu Chien Constance, Muhamed Shamir Jaffar Hussein, Claude J. Renaud

    Background: Artificial intelligence (AI) is disrupting healthcare and health professions education (HPE), creating complex ethical challenges. Despite existing governance frameworks, postgraduate and continuing professional development (CPD) learners require stronger micro‐level ethical competence. However, AI‐ethics remains insufficiently integrated into postgraduate/CPD curricula with few real‐world reflective and interprofessional strategies, raising concerns regarding ethical preparedness. The aim of this study is to map how AI ethics is taught within postgraduate/CPD HPE, drawing on principlism, an ethical framework espousing the principles of autonomy, beneficence, non‐maleficence and justice and transformative learning theory (TLT), which explains how critical reflection transforms professional assumptions, perspectives and practice. Method: A systematic search of six databases (2000–2025) was conducted to identify relevant sources. Data extraction captured study design, educational setting, pedagogical strategies and ethical themes. Findings were synthesised descriptively and narratively to examine empirical rigour, theoretical alignment and relevance to contemporary generative‐AI developments. Results: Sixteen eligible sources were identified. Only 31% were empirical studies. The evidence reflected a strong Western worldview. AI‐ethics education for postgraduate/CPD learners was limited, often superficial and reliant on varied but weakly evaluated pedagogies. Principlism appeared frequently but mostly implicitly, whereas explicit application of TLT was rare. Major gaps included low empirical and pedagogical rigour, minimal interprofessionalism and marked temporal anachronism, as most studies predated the advent of generative AI. Conclusion: AI‐ethics education in postgraduate/CPD HPE remains conceptually rich but pedagogically underdeveloped. Effective curricula require structured, theory‐anchored, interprofessional and culturally responsive approaches. Integrating principlism and TLT as ethical and pedagogical frameworks may strengthen ethical competence and preparedness.


  • Two-week postoperative duplex ultrasound as a clinical workflow tool for risk stratification of radiocephalic arteriovenous fistulas

    by Claude Jeffrey Renaud, Allen Yan Lun Liu, Clarice Chua Kah Hwei, Tan Khin Swee Elisabeth, Abdul Haque bin Abdul Jabbar, Lee Wei Han, Chuo Ren Leong

    Background: Radiocephalic arteriovenous fistulas (RCAVFs) are the preferred initial haemodialysis access but are limited by high non-maturation rates, particularly in populations with smaller vessels and high diabetic burden. Preoperative duplex ultrasound (DUS) guides vessel selection but inconsistently predicts postoperative haemodynamic adaptation. We evaluated whether a standardised 2-week postoperative DUS checkpoint could function as a clinical workflow tool for early risk stratification and long-term patency prediction. Methods: In this prospective single-centre study, 57 patients undergoing primary RCAVF creation were followed for up to 10 years. Two-week postoperative DUS assessed vein diameter (VD), brachial artery flow (BAF) and resistive index (RI). Receiver operating characteristic analysis identified thresholds predicting 6-week Kidney-Disease-Outcomes-Quality-Initiative-defined maturation. Kaplan–Meier and Cox regression analyses evaluated long-term primary (PP) and secondary patency (SP). Results: Six-week maturation occurred in 56%, and functional maturation in 61% of patients initiated on dialysis. Two-week VD demonstrated the strongest discrimination for maturation (AUC 0.81, 95% CI 0.50–0.84, p = 0.01), followed by BAF (AUC 0.72, 95% CI 0.65–0.90, p = 0.02). RI showed weaker performance (AUC 0.67, 95% CI 0.50–0.83, p = 0.05). A VD p = 0.01). BAF predicted early maturation but not long-term PP and SP. Early vein and flow expansion kinetics were not independently associated with long-term outcomes. Conclusions: A 2-week postoperative DUS checkpoint provides actionable early structural risk stratification after RCAVF creation. Early structural calibre reflects adaptive remodelling and independently predicts long-term PP, supporting integration of this checkpoint into routine practice.

  • Practice and Outcome Trends of Peritoneal Dialysis in Chronic Kidney Disease Patients With Liver Cirrhosis and Chronic Heart Failure Complicated by Symptomatic Ascites—A Scoping Review

    by Claude J. Renaud, Tricia Mae Wong, Muhamed Shamir Jaffar Hussein

    Background: The rising growth of patients with end‐stage kidney disease (ESKD) associated with chronic liver disease (CLD) and refractory chronic heart failure (CHF) associated with advanced chronic kidney disease (CKD) complicated by ascites presents serious renal replacement therapy (RRT) challenges. Haemodialysis is often poorly tolerated owing to increased hemodynamic instability, bleeding, and encephalopathy risks. Peritoneal dialysis (PD) has emerged as a promising alternative, but its adoption and efficacy are not consistently supported by existing literature, and there lacks guideline consensus.Methods: We thus used a scoping review approach to more accurately map the literature on PD practice and outcomes in this population.Results: We identified 18 observational studies involving 627 ESKD patients with CLD/ascites and 222 advanced CKD patients with CHF/ascites.We found practice patterns revealing higher adoption of PD for CLD/ascites in Asia, reflecting the heavier regional PD and viral hepatitis penetration, while there was unique usage for CHF in Western settings. Across contexts, PD demonstrated adaptability for diverse patient profiles.PD as urgent‐start and incremental therapy enabled both long‐term controlled paracentesis and dialysis while maintaining haemodynamic stability, optimal nutritional status and particularly in CHF improved symptom control, reduced hospitalisation, and lowered diuretics reliance. Mechanical complications were rare and typically manageable whilst peritonitis rates were comparable without impacting technique failure. Survival outcomes were also comparable or superior.Conclusions: Our findings add valuable insights to PD as a feasible and safe long‐term RRT option across the ascitic CKD spectrum. Broader consensus is nonetheless needed on its expansion as a first‐line therapy and bridge to both palliation and transplantation.


  • Clinical experience with intraperitoneal sodium thiosulphate for calciphylaxis in peritoneal dialysis: A case series

    by Yuan Kai Teh, Claude J Renaud

    Calciphylaxis is an uncommon but life-threatening syndrome in end-stage kidney disease, characterised by painful medial and intimal calcification of the arterioles in the deep dermis and subcutaneous tissues. Intravenous sodium thiosulfate serves as an off-label but effective treatment in haemodialysis patients. However, this approach confers considerable logistical challenges for affected peritoneal dialysis patients. In this case series, we demonstrate that intraperitoneal administration can be a safe, convenient and long-term alternative.


  • Open Access

    A real-world study on SGLT2 inhibitors and diabetic kidney disease progression

    by Allen Yan Lun Liu, Serena Low, Ester Yeoh, Eng Kuang Lim, Claude Jeffrey Renaud, Selene Tse Yen Teoh, Grace Feng Ling Tan, Chung Cheen Chai, Bo Liu, Tavintharan Subramaniam, et al.

    Randomized controlled trials have demonstrated the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). However, real-world data on CKD progression and the development of end-stage kidney disease (ESKD) remains scarce. Our aim was to study renal outcomes of people with diabetic kidney disease (DKD) using SGLT2is in a highly prevalent DKD population. Between 2016 and 2019 we recruited T2DM patients in the renal and diabetic clinics in a regional hospital in Singapore. Patients prescribed SGLT2is were compared with those on standard anti-diabetic and renoprotective treatment. The outcome measures were CKD progression [a ≥25% decrease from baseline and worsening of estimated glomerular filtration rate (eGFR) categories according to the Kidney Disease: Improving Global Outcomes guidelines] and ESKD (eGFR 2). We analysed a total of 4446 subjects; 1598 were on SGLT2is. There was a significant reduction in CKD progression {hazard ratio [HR] 0.60 [95% confidence interval (CI) 0.49–0.74]} with SGLT2is. The HR for eGFR ≥45 mL/min/1.73 m2 and 15–44 mL/min/1.73 m2 was 0.60 (95% CI 0.47–0.76) and 0.43 (95% CI 0.23–0.66), respectively. There was also a reduction in risk for developing ESKD for the entire cohort [HR 0.33 (95% CI 0.17–0.65)] and eGFR 15–44 mL/min/1.73 m2 [HR 0.24 (95% CI 0.09–0.66)]. Compared with canagliflozin and dapagliflozin, empagliflozin showed a sustained risk reduction of renal outcomes across CKD stages 1–4. This real-world study demonstrates the benefits of SGLT2is on CKD progression and ESKD. The effect is more pronounced in moderate to advanced CKD patients.


  • Looking beyond catheter removal in polymicrobial peritonitis from unusual enteric bugs

    by Jin Wen Rachael Nai, Claude Jeffrey Renaud


  • Effect of ultra‐low dose and standard heparin locks on early tunnelled dialysis catheter outcomes in low‐risk dialysis patients

    by Claude J Renaud, Eng Kuang Lim, Samuel J Tho, Lee Ying Yeoh

    Aim: Initial heparin locks instilled after tunnelled dialysis catheter (TDC) insertion can leak causing systemic anticoagulation and also promote staphyloccocal biofilm formation, predisposing to catheter‐related infection (CRI). The 1000 U/mL concentration is thus advocated as the optimal dose for preventing catheter bleeding and malfunction. The effect of lower heparin concentrations on further lowering these complications is not known. We compared early TDC outcomes between a non‐standard ultra‐low (500 U/mL) and standard initial heparin locks (1000 and 5000 U/mL).Methods: This was a retrospective study on prospectively collected data on 238 de novo internal jugular TDCs placed by nephrologists. Cases were categorized into groups 1, 2 and 3, according to initial heparin lock: 500 [n = 30], 1000 [n = 180] and 5000 U/mL [n = 28] respectively. Bleeding and malfunction within 24 h of TDC insertion, 30 days CRI‐free catheter survival and the effects of clinical and laboratory factors on bleeding were evaluated.Results: Bleeding events were similar in groups 1, 2 and 3 (7 vs 14 vs 13%, respectively, P = 0.61). Malfunction was only seen in group 2 (3.3%). Thirty‐day CRI‐free catheter survival was comparable (96 vs 98 vs 97%, respectively, P = 0.22), giving a cumulative CRI rate of 0.76/1000 catheter days. All CRIs were staphylococcal. Univariate analysis did not reveal any significant predictors of catheter bleeding.Conclusion: Immediate TDC bleeding, malfunction and CRI rate are not influenced by heparin lock concentrations ≤5000 U/mL in this low‐risk cohort. However this needs to be corroborated in higher risk patients.


  • Angiography (Fistulography)

    by Luc Turmel-Rodrigues, Claude J. Renaud


  • Psychological and Clinical Issues

    by Luc Turmel-Rodrigues, Claude J. Renaud